EHCHealthcare · Medical Care FacilitiesThe 13 Wall Street analysts covering Encompass Health Corp. hold a median 12-month price target of $155 — +9.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Encompass Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (94): Analysts have, on balance, been raising their forecasts.
Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on EHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.9% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2026 | UBS | Maintains | Buy | — |
| 30 Oct 2026 | Keybanc | Maintains | Overweight | $147 → $150 |
| 30 Oct 2026 | TD Cowen | Maintains | Buy | $140 → $150 |
| 30 Oct 2026 | Truist Securities | Reiterates | Buy | $150 → $156 |
| 30 Oct 2026 | UBS | Maintains | Buy | $155 → $165 |
| 29 Oct 2026 | Barclays | Maintains | Overweight | $144 → $151 |
| 10 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 10 Aug 2026 | TD Cowen | Maintains | Buy | $125 → $140 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $140 → $150 |
| 7 Aug 2026 | UBS | Maintains | Buy | — |
| 7 Aug 2026 | UBS | Maintains | Buy | $150 → $155 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $140 → $144 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | — |
| 28 May 2026 | TD Cowen | Initiates | Buy | — |
| 28 May 2026 | TD Cowen | Initiates | Buy | $125 |
| 5 May 2026 | Barclays | Maintains | Overweight | — |
| 6 Feb 2026 | Barclays | Maintains | Overweight | — |
| 30 Oct 2025 | Barclays | Maintains | Overweight | — |
| 2 Oct 2025 | UBS | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EHC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Encompass Health Corp. returned +21.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 50% of US stocks
Cheaper than 19% of US stocks
Cheaper than 33% of US stocks
Higher than 50% of US stocks
Higher than 58% of US stocks
Higher than 98% of US stocks
Higher than 76% of US stocks
Higher than 70% of US stocks
Higher than 85% of US stocks
Higher than 92% of US stocks
Higher than 67% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Encompass Health Corp. has a market value of $13.3B and an enterprise value of $17.1B.
Revenue in the twelve months to 30 June 2026: $6.2B. The latest quarter grew 8.9% year on year.
Net income over the same four quarters: $833.3M, a 13.4% net margin.
Diluted earnings per share, trailing twelve months: $6.14.
Free cash flow in the twelve months to 30 June 2026: $413.4M.
Encompass Health Corp. spent $247.0M on share buybacks and $75.2M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 21.8×; forward P/E: 19.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.62%, paying out 13% of earnings.
Encompass Health Corp. employs 30,226 people — $205K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Encompass Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights that Encompass Health (EHC) rose 9.52% in one week and asks whether it may appeal to momentum investors.
Why it matters — EHC watchers may note the reported weekly gain and the article’s focus on the stock’s momentum.
Encompass Health (EHC) is at a 52-week high. The article examines the company’s fundamentals for clues about whether further gains may be possible.
Why it matters — EHC watchers may be interested in the company fundamentals discussed in the context of its recent high.
A Zacks Investment Research item presents Encompass Health (EHC) as a strong value stock and points readers to Zacks Style Scores for identifying stocks.
Why it matters — EHC watchers may note the article’s positive characterization of the stock as a value pick.
Encompass Health raised its full-year 2026 outlook after reporting Q3 revenue growth of 8.9%, adjusted EBITDA growth of 15.5%, and adjusted EPS growth of 23.6%. The company attributed growth to higher discharges, increased patient acuity, and higher revenue per discharge.
Why it matters — The results and raised outlook give EHC watchers an update on the company’s performance and expectations for 2026.
Encompass Health held its third-quarter 2026 earnings conference call on October 29, 2026. The excerpt lists company executives and analysts participating but provides no financial results or other substantive discussion.
Why it matters — EHC watchers are alerted to the Q3 2026 call, though the excerpt does not include details on the company’s performance or outlook.
The 13 Wall Street analysts covering Encompass Health Corp. have a median 12-month price target of $155, with estimates ranging from $142 to $177. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Encompass Health Corp., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Encompass Health Corp. 87 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Encompass Health Corp. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +9.9% from the last close, and Ticker Nerd's factor model ranks Encompass Health Corp. 87 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Encompass Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $142 to $177 over the next 12 months.
Encompass Health Corp. returned +21.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Encompass Health Corporation is a post-acute healthcare company focused on inpatient rehabilitation hospitals. The company provides specialized, facility-based care for patients recovering from strokes, neurological disorders, brain and spinal cord injuries, cardiac and pulmonary conditions, complex orthopedic cases, amputations, and other serious illnesses or injuries.
The most recent item we track (Zacks Investment Research, 2 Nov 2026): "Encompass Health (EHC) Is Up 9.52% in One Week: What You Should Know". Zacks Investment Research highlights that Encompass Health (EHC) rose 9.52% in one week and asks whether it may appeal to momentum investors.
Encompass Health Corporation is a post-acute healthcare company focused on inpatient rehabilitation hospitals. The company provides specialized, facility-based care for patients recovering from strokes, neurological disorders, brain and spinal cord injuries, cardiac and pulmonary conditions, complex orthopedic cases, amputations, and other serious illnesses or injuries. Its services combine medical, nursing, therapy, and ancillary support to help patients regain functional ability, independence, and quality of life. Encompass Health operates a national network of rehabilitation hospitals across the United States and Puerto Rico, making it a significant provider in the inpatient rehabilitation market. Based in Birmingham, Alabama, Encompass Health plays a central role in delivering coordinated recovery care for patients who need intensive, medically supervised rehabilitation after hospitalization.
CEO Mr. Mark J. Tarr · 30,226 employees · United States · https://www.encompasshealth.com
